|
|
[資源]
The year's new drugs & biologics 2014 - Part II: Trends & challenges
2014 was a year of continued high activity in the pharma and biotech industry, as evidenced in part I of this annual two-part review article published last month in this journal (1). As of December 23, 2014, a total of 55 new chemical and biological entities had reached their first markets worldwide, together with another 29 important new line extensions. Another 19 products were approved for the first time during the year but not yet launched by December 23. Furthermore, during the now-traditional year-end sprint, several regulatory agencies issued last-minute approvals for other compounds that missed the deadline for inclusion in that article, bringing the total of new approvals for the year to a somewhat higher number. In addition to the successful development, registration and launch of new drugs and biologics, there are various other trends and tendencies that serve as indicators of the overall health and status of the industry. These include the pursuit of novel programs designed by regulators to stimulate the development of drugs for diseases that are currently under-treated; the regular and pragmatic culling by companies of their R&D pipelines; and the decision to unify pipelines, portfolios and sales forces through mergers and acquisitions.
和如下資源組成完整的2014年全球新藥研發(fā)報(bào)告:
http://www.gaoyang168.com/bbs/viewthread.php?tid=8550491 |
» 本帖附件資源列表
-
歡迎監(jiān)督和反饋:小木蟲僅提供交流平臺(tái),不對該內(nèi)容負(fù)責(zé)。
本內(nèi)容由用戶自主發(fā)布,如果其內(nèi)容涉及到知識(shí)產(chǎn)權(quán)問題,其責(zé)任在于用戶本人,如對版權(quán)有異議,請聯(lián)系郵箱:xiaomuchong@tal.com
- 附件 1 : 2014_II.pdf
2015-03-27 10:21:46, 241.73 K
» 收錄本帖的淘帖專輯推薦
» 猜你喜歡
» 本主題相關(guān)價(jià)值貼推薦,對您同樣有幫助:
|